Nature, Published online: 13 November 2024; doi:10.1038/s41586-024-08207-0

In mouse and nonhuman primate models, treatment with selective, long-acting neurokinin 2 receptor agonists aids weight loss by suppressing appetite and increasing energy expenditure, as well as by increasing insulin sensitivity.